Table 2 WHO – Pipeline Zika virus (ZIKV) vaccines (in preclinical development) (last updated January 2017) January 2017)
From: Zika vaccines and therapeutics: landscape analysis and challenges ahead
Platform | Candidate vaccine name | Developer/Collaborators | Replicating virus (Yes/No) | Antigen | Adjuvant |
|---|---|---|---|---|---|
Inactivated whole target organism | BK1603 | BIKEN | No | ZIKV full genome | To be determined |
Inactivated whole target organism | Â | Bio-Manguinhos in house development and Sanofi Pasteur/WRAIR (discontinued in 2017) | No | ZIKV full genome | Alum |
Recombinant subunit (non- VLP) | Â | Bio-Manguinhos partnership | No | ZIKV E protein | Alum |
Recombinant viral vector | Â | Bio-Manguinhos/Aggeu Magalhaes (FIOCRUZ) | Yes | PrM/E and PrM/E/NS1 | None |
Live, attenuated recombinant virus | Â | Brazilian Ministry of Health agreement with University of Texas | Yes | rZIKV | None |
| Â | Â | Â | Â | rZIKV NS1 | Â |
Inactivated whole target organism | Butantan ZIKV | Butantan | No | ZIKV full genome | Alum |
Live, attenuated target organism | Butantan attenuated ZIKV | Butantan | Â | ZIKV full genome | None |
Inactivated virus + aluminum adjuvant | ZIKV | Emergent BioSolutions | No | ZIKV full genome | Aluminum |
Recombinant viral vector | GEO-ZM05 | GeoVax/University of Georgia/CDC Atlanta, US | No | ZIKV PrM/E + NS1 | None |
SAM | WT | GSK-NIH | Yes | ZIKV prM/E | Â |
SAM | CO | GSK-NIH | Yes | ZIKV prM/E | Â |
SAM | VRC_5283 | GSK-NIH | Yes | ZIKV prM/E | Â |
SAM | VRC_5288 | GSK-NIH | Yes | ZIKV prM/E | Â |
Recombinant subunit (non-VLP) | ZIK-80E | Hawaii Biotech, Inc. | No | Â | Â |
Recombinant subunit VLP (non-fusion) | ZIKVLP | Institut Pasteur Shanghai, China | No | Â | Â |
Recombinant viral vector | NI.LV-ZIK | Institut Pasteur, Paris, France | No | ZIKV prM/E | None |
Recombinant viral vector | ChAdOx1-Zk | Jenner Institute | Â | ZIKV prM/E | None |
Inactivated whole target organism | KAKETSUKEN ZIKV | Kaketsuken | No | ZIKV full genome | TBD |
Inactivated whole target organism |  | NewLink Genetics | No | ZIKV prM/E + NS1 | TBD |
Recombinant subunit VLP (fusion) | Â | NewLink Genetics | No | ZIKV prM-E | TBD |
Live, attenuated target organism | rZIKV/D2D30 | NIAID | Yes | ZIKV prM/E | None |
Live, attenuated target organism | rZIKV/D4D30 | NIAID | Yes | ZIKV prM/E | None |
Live, attenuated target organism | rZIKVD30 | NIAID | Yes | ZIKV full genome | None |
Recombinant viral vector | Â | NIAID | Yes | Â | None |
Sf9 cells/Baculo | ZIKV envelope dimers (EnvD) | Novavax, Inc. | No | ZIKV E protein | Matrix M adjuvant or aluminum hydroxide |
nanoDNA/ZIKA-LAMP chimera construct | LAMP-ZIKA nanoDNA | Pharos Biologicals | No | ZIKV prM/E | Â |
Recombinant subunit (non-VLP) | ZIKA recombinant | Protein Sciences/Sinergium Biotech/Lab Liomont | No | ZIKV E protein | Aluminum based |
Peptide | Replikins Zika Vaccine and Bocker | Replikins Ltd. | No | Synthetic Peptides | None |
Recombinant viral vector | Chimerivax-Zika | Sanofi Pasteur |  | ZIKV prM/E + NS1 | None |
Recombinant viral vector | SCV-CHIKV+ZIKV+YF | Sementis Ltd. | No | ZIKV, yellow fever, and CHIKV surface antigens | None |
Recombinant viral vector | SCV-CHIKV+ZIKV | Sementis Ltd. | No | ZIKV and CHIKV surface antigens | None |
Recombinant viral vector | SCV-ZIKV | Sementis Ltd. | No | ZIKV surface antigens | None |
Inactivated whole target organism | Â | Takeda | No | ZIKV full genome | Alum |
Subunit | Â | Tours University | No | Â | Â |
VLP HBV-Zika | |||||
Prime-boost | Â | U1187 INSERM (CYROI, La Reunion) | Â | Â | Â |
Live attenuated + ZIKV exosome | |||||
Inactivated whole target organism | Â | Valneva | No | ZIKV full genome | Aluminum hydroxide |
Recombinant viral vector | VXA-Zikavax | Vaxart | Â | ZIKV prM/E | Â |
VLP | VBI-2501A | VBI Vaccines | No | ZIKV E + NS1 |  |
DNA | Â | WRAIR/BIDMC/Harvard | No | ZIKV prM/E | Â |
Recombinant viral vector | Â | WRAIR/BIDMC/Harvard | Â | ZIKV prM/E | Â |